Event Recordings
Session I - Big Opportunities and Pressing Issues in Drug Discovery I
From Molecules to Models: Rethinking Drug Development in the Age of AI
Vijay Pande, PhD
General Partner, Andreessen Horowitz
How Big Data and Technology are Disrupting Healthcare
Marc Tessier-Lavigne, PhD
CEO, Xaira Therapeutics
AI in Drug Discovery: Separating Hype from Reality
Dan Sheeran, MBA
General Manager, Healthcare and Life Science, Amazon Web Services
Session II - Big Opportunities and Pressing Issues in Drug Discovery II
A First in Class Activin Signaling Inhibitor for Pulmonary Arterial Hypertension- Humbling Experiences on the Road from Academia to Industry
Dean Li, MD, PhD
Executive Vice President and President, Merck Research Laboratories
AI's Impact on Drug Discovery and Development
Shweta Maniar
Global Director of Healthcare and Life Sciences, Google Cloud
Obesity Beyond Incretins
Ruth Gimeno, PhD
Group Vice President, Diabetes, Obesity & Cardiometabolic Research and Early Clinical Development, Eli Lilly and Company
Sustaining Progress During Times of Uncertainty
Stephen Hoge, MD
President, Moderna
Session IV - Foundation, Funding, and Regulatory Perspectives
A Decade of Molecular Cell Atlases
Stephen Quake, D.Phil
Head of Science, Chan Zuckerberg Initiative
The PICI Science-to-Startup Model: De-Risking Cancer Discovery and Accelerating Access to Cures
Karen Knudsen, MBA, PhD
CEO, Parker Institute for Cancer Immunotherapy
Funding Science Through PPP's: CIRM and CGT Research
Jonathan Thomas, PhD, JD
President and CEO, CIRM
Session IV – Panel Discussion
Stephen Quake, D.Phil
Head of Science, Chan Zuckerberg Initiative
Karen Knudsen, MBA, PhD
CEO, Parker Institute for Cancer Immunotherapy
Jonathan Thomas, PhD, JD
President and CEO, CIRM
Session V - Venture Capital Perspectives on Drug Discovery
Session V Panel Discussion
Moderator: Karin Immergluck, PhD
Facilitator: Kuldev Singh, MD
Srini Akkaraju, MD, PhD
Founder & Managing Partner, Samsara BioCapital
Caroline Stout
Partner, EcoRI Capital
Christoph Lengauer, PhD, MBA
Co-Founder & CSO, Curie.Bio
Francis Ho, PhD
Partner, Walden Catalyst
Session VI - New Paradigms for Genetic Medicines
Samarth Kulkarni, PhD
CEO and Chairman of the Board, CRISPR Therapeutics
Antisense Based Therapies
Frank Bennett, PhD
CSO, Ionis